

IN THE SPECIFICATION:

Please note that the amendments to the specification are shown below in clean form for clarity. A marked up version showing the changes made is attached.

Please substitute the following replacement paragraph for the paragraph located at page 2, lines 5 through 9 of the specification.

61
RMD
4/15/03

This application is a continuation-in-part of application serial number 09/274,048 filed 22 March 1999, now U.S. Patent No. 6,284,733, issued 4 September 2001, which is a continuation of application serial number 08/981,557 filed 5 December 1997, now U.S. Patent No. 5,885,966, issued 23 March 1999, as a national entry application under PCT/NL96/00223 filed 6 June 1996, which claims priority under U.S. application 08/477,298 ~~now abandoned~~ filed 7 June 1995 and U.S. application 08/476,013 ~~now abandoned~~ filed 7 June 1995.

Please substitute the following replacement paragraph for the paragraph located at page 13, lines 13 to 16 of the specification.

62

Figure 4: Immunocastration efficacy score of several groups of pigs immunized with GnRH-tandem-dimer peptides (62 mg) conjugated to ovalbumine and Specol used as an adjuvant. The starting peptide was GnRH tandem (Cys-OH) dimer (abbreviated Cys-OH). Of this peptide all alanine scan peptides were used for immunization. Immunocastration efficacy was rated on a scale of 1 to 4 (1 = immunocastration did not occur, 2 = a minority of the pigs were immunocastrated, 3 = a majority of the pigs were immunocastrated, and 4 = all pigs were immunocastrated).

IN THE CLAIMS:

Please note that the claim amendments are shown below in clean form for clarity. A marked up version showing the changes made is attached.

Please cancel claims 1, 2, 3, 4, 20, 21, 26, 34, 35, 36, 51 and 52 without prejudice or disclaimer.